Iqvia Holdings Inc (IQV) Position Trimmed by Buffington Mohr McNeal

Share on StockTwits

Buffington Mohr McNeal lowered its stake in Iqvia Holdings Inc (NYSE:IQV) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,640 shares of the medical research company’s stock after selling 250 shares during the period. Buffington Mohr McNeal’s holdings in Iqvia were worth $1,585,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in IQV. BlackRock Inc. lifted its position in Iqvia by 4.6% during the third quarter. BlackRock Inc. now owns 10,634,928 shares of the medical research company’s stock valued at $1,379,777,000 after buying an additional 464,880 shares during the period. Canada Pension Plan Investment Board lifted its position in Iqvia by 0.6% during the third quarter. Canada Pension Plan Investment Board now owns 7,487,766 shares of the medical research company’s stock valued at $971,463,000 after buying an additional 40,978 shares during the period. Oregon Public Employees Retirement Fund lifted its position in Iqvia by 44,777.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 7,140,389 shares of the medical research company’s stock valued at $61,000 after buying an additional 7,124,478 shares during the period. Capital Research Global Investors lifted its position in Iqvia by 51.8% during the third quarter. Capital Research Global Investors now owns 3,055,858 shares of the medical research company’s stock valued at $396,467,000 after buying an additional 1,042,431 shares during the period. Finally, AQR Capital Management LLC lifted its position in Iqvia by 10.2% during the third quarter. AQR Capital Management LLC now owns 2,996,536 shares of the medical research company’s stock valued at $388,771,000 after buying an additional 277,477 shares during the period. Institutional investors and hedge funds own 93.62% of the company’s stock.

IQV opened at $141.85 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $28.38 billion, a PE ratio of 32.53, a P/E/G ratio of 1.63 and a beta of 0.88. Iqvia Holdings Inc has a 1 year low of $91.57 and a 1 year high of $143.42.

Iqvia (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.03. The firm had revenue of $2.69 billion during the quarter, compared to analyst estimates of $2.62 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. Iqvia’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.40 EPS. Sell-side analysts forecast that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

Several brokerages have commented on IQV. Barclays reissued a “buy” rating and set a $155.00 price objective on shares of Iqvia in a research report on Friday. Piper Jaffray Companies raised their price objective on Iqvia to $148.00 and gave the company a “neutral” rating in a research report on Friday. UBS Group set a $170.00 price objective on Iqvia and gave the company a “buy” rating in a research report on Friday. Morgan Stanley raised their price objective on Iqvia from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Monday, December 3rd. Finally, Jefferies Financial Group raised Iqvia from a “hold” rating to a “buy” rating and raised their price objective for the company from $136.00 to $150.00 in a research report on Friday, January 18th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $143.38.

In other news, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of Iqvia stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total value of $391,498,083.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronald A. Rittenmeyer sold 3,840 shares of Iqvia stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $130.00, for a total value of $499,200.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,751,273 shares of company stock valued at $835,335,596. 6.00% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This report was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/4163053/iqvia-holdings-inc-iqv-position-trimmed-by-buffington-mohr-mcneal.html.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Further Reading: Stock Split

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GeneNews  Stock Price Up 6.3%
GeneNews Stock Price Up 6.3%
Armadale Capital  Stock Price Down 7.6%
Armadale Capital Stock Price Down 7.6%
Caleres  Price Target Cut to $26.00 by Analysts at Loop Capital
Caleres Price Target Cut to $26.00 by Analysts at Loop Capital
G-III Apparel Group  Price Target Raised to $39.00 at Barclays
G-III Apparel Group Price Target Raised to $39.00 at Barclays
Vuzix  Stock Rating Upgraded by Zacks Investment Research
Vuzix Stock Rating Upgraded by Zacks Investment Research
HANG SENG BK LT/S  Rating Increased to Buy at UBS Group
HANG SENG BK LT/S Rating Increased to Buy at UBS Group


© 2006-2019 Ticker Report